Morocco medicine price database

YPEVA

BEVACIZUMAB

Public price

9,51 MAD

Active substance

BEVACIZUMAB

Laboratory

SOTHEMA

What is this medicine?

A vascular endothelial growth factor inhibitor used for the treatment of various types of metastatic and recurrent cancers.

Verified summary

BEVACIZUMAB, SOLUTION A DILUER POUR PERFUSION IV, 400 MG (25 MG / ML), BOITE D'UN FLACON DE 16 ML

Common uses

Metastatic colorectal cancer,Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer,Recurrent glioblastoma in adults,Metastatic renal cell carcinoma,Persistent, recurrent, or metastatic cervical cancer,Epithelial ovarian, fallopian tube, or primary peritoneal cancer

Class

vascular endothelial growth factor inhibitor

Laboratory

SOTHEMA

Hospital price

9,33 MAD

Strength

400 MG (25 MG / ML)

Form

SOLUTION A DILUER POUR PERFUSION IV

Presentation

BOITE D'UN FLACON DE 16 ML

Commercial status

Commercialisé

This information is informational and must be confirmed by a pharmacist or doctor. Do not change medicine or dosage based only on this page.

Price history

Reference price recorded since 2026-06-01: 9,51 MAD

Available presentations and strengths

Medicines with the same active substance